Details for Patent: 7,812,049

Which drugs does patent 7,812,049 protect, and when does it expire?

Patent 7,812,049 protects RHOFADE and is included in one NDA.

Summary for Patent: 7,812,049

Title:	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists
Abstract:	The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .alpha..sub.1-adrenergic receptor (.alpha..sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
Inventor(s):	Shanler; Stuart D. (New York, NY), Ondo; Andrew (Las Cruces, NM)
Assignee:	Vicept Therapeutics, Inc. (Malvern, PA)
Application Number:	10/763,807
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,812,049
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 7,812,049

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes						TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM